Skip to content

APOTHEEK MANN

Active
Private limited company (pre-2019)founded 200917 yrs activeJan Van Rijswijcklaan 82, 2018 Antwerpen, BelgiumKBO/BCE: BE 0815.855.617
Summary

APOTHEEK MANN has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €358,394 and a net result of €147,671. Equity is growing by ~9.2% per year across the filed fiscal years. Its solvency ranks better than 45% of 11293 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).

Risk analysisWatch ReportCompare
APOTHEEK MANNActiveChecked score 69/100
Risk analysis ReportCompare

Overview

What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€1.1mtotal assets 2025
Staff
2.2 FTE
Equity
€358,394
Profit
€147,671
Turnover not published (abridged schema)
Financially healthy?
69 Healthy Checked score 2025
Bankruptcy chance 12 m
0.6%
Who decides
Parent
PHARMA COVA · 100%
Accounts 1 d early0 of 3 deeds read
Why 69- Higher-failure-rate sector+ Annual accounts: healthy financial profile+ Long track recordLatest accounts filed on timeShow the evidence

Checked score

Score 2025
69 / 100
Healthy
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability86▲+9
Solvency58▲+5
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €24,000 at 30 days acceptable
Liquidity ample (current ratio 1.69 against 1.54 in 2024; short-term debt: 26.9% and cash: 1.8% of total assets), but 67.2% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
32.8%
Return on assets
13.5%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 17 years 0 20 y
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
1 d early
2024
25 d early
2023
29 d late
2022
7 d late
2021
30 d late
2020
27 d late
2019
129 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 28 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 7 August (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · abbreviated…
  2. Highest result since 2018net €147,671 ▲87.8%
  3. Annual accounts filedfiscal year 2024 · abbreviated…

Key points

  • Positive: Result rose in 2025from €78,626 to €147,671 ▲ 87.8% View
  • Positive: Among the best 18% on net resultsector median €28,692 · 11,279 companies €147,671 View
  • Positive: 8 profitable years in a rowprofit 2025: €147,671 8 years View
  • Controlled by PHARMA COVA 100% View

By topic

Financials

Fiscal year
2025
Total assets
€1.1m
Profit
€147,671
Solvency
32.8%
Total assets▼ 6.0%
Net result
20182025
Go to Financials

Timeline

Events
13
Since
2017
Next accounts
by 31-07-2027
  1. 30-07-2026Annual accounts filed
  2. 31-12-2025Highest result since 2018
  3. 06-07-2025Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company (pre-2019)
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
26-06-2009
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure